Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
C4 Therapeutics Inc(CCCC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CCCC
09/25/2026: CCCC (1-star) is currently NOT-A-BUY. Pass it for now.
C4 Therapeutics is a clinical-stage biotechnology company developing targeted protein degradation therapies to treat complex cancers. The company's primary strength lies in its proprietary TORPEDO platform, which has demonstrated capability in drug discovery and attracted several strategic pharmaceutical partnerships. Its growth story is centered on advancing clinical-stage candidates like CFT7455 and CFT8634 toward potential regulatory approval. Investors must consider significant risks, including clinical trial outcomes, high cash burn, and intense competition in the protein degradation space. This stock is best suited for growth-oriented investors who are comfortable with the high volatility typical of clinical-stage biotechnology companies and can monitor long-term clinical development progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | The company offers high-growth potential linked to its innovative platform and clinical pipeline. |
| Momentum investor | Mixed fit | Momentum is highly sensitive to clinical trial data readouts and partnership news. |
| Value investor | Weak fit | As a pre-revenue biotech, the company lacks the earnings metrics required for traditional value analysis. |
| Dividend investor | Weak fit | The company does not pay dividends and is in an aggressive capital-reinvestment phase. |
| Low-risk investor | Weak fit | The inherent risks of drug development make this stock unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp price fluctuations based on trial results and regulatory news. |
| Valuation risk | High | Valuation is speculative as it relies on future potential of drugs in development rather than current profits. |
| Competition risk (targeted protein degradation) | Medium / high | The field is crowded with many players attempting to solve similar therapeutic challenges. |
| Business quality | Medium | The company has a strong platform, but business quality remains tied to the execution of clinical success. |
| Dividend income | Low / none | No income generation is expected for the foreseeable future. |
| Execution risk | High | Failure to advance clinical programs efficiently directly threatens the company's long-term viability. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -20.51% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 366.61M USD | Price to earnings Ratio - | 1Y Target Price 13.33 |
Price to earnings Ratio - | 1Y Target Price 13.33 | ||
Volume (30-day avg) 2.2M shares | Beta 2.94 | 52 Weeks Range 1.69 - 5.17 | Updated Date 09/26/2026 |
52 Weeks Range 1.69 - 5.17 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Upfront payments, milestone payments, and potential royalties from strategic research and development partnerships. | Revenue comes primarily from partnerships where larger pharmaceutical companies pay C4 to use its technology. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 182.11M | Price to Sales(TTM) 10.46 |
Enterprise Value 182.11M | Price to Sales(TTM) 10.46 | ||
Enterprise Value to Revenue 5.2 | Enterprise Value to EBITDA -0.42 | Shares Outstanding 123.03M | Shares Floating 94.51M |
Shares Outstanding 123.03M | Shares Floating 94.51M | ||
Percent Insiders 0.84 | Percent Institutions 103.1 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About C4 Therapeutics Inc
Exchange NASDAQ | Headquarters Watertown, MA, United States | ||
IPO Launch date 2020-10-02 | CEO, President & Director Mr. Andrew J. Hirsch M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 104 | Website https://www.c4therapeutics.com |
Full time employees 104 | Website https://www.c4therapeutics.com | ||
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.